Clinical trials in biologic therapy for Crohn's disease

Comparing designs and data

Gary R. Lichtenstein, Stephen B. Hanauer, Edward Vincent Loftus, Jr

Research output: Contribution to journalArticle

Abstract

Crohn's disease is a chronic inflammatory bowel disease with no known cure, estimated to occur in more than 500,000 Americans. Induction and long-term maintenance of remission are the major goals of Crohn's disease therapy. Over the past several decades, standard therapy for Crohn's disease patients has included immunomodulatory drugs such as azathioprine and 6-mercaptopurine, anti-inflammatory drugs such as 5-aminosalicylate, steroids, and antibiotics. Unfortunately, many patients become refractory to therapy over time or dependent on therapies such as corticosteroids, which are not feasible for long-term use. Over the past decade, several biologic agents have emerged with potential to induce response of active disease and maintain remission in Crohn's disease patients. Most of these agents, including infliximab, adalimumab, and certolizumab pegol, target the pro-inflammatory cytokine tumor necrosis factor. Several pivotal clinical trials have been conducted to investigate the safety and efficacy potential of these agents. Infliximab was evaluated in the key ACCENT I and II studies, while certolizumab pegol has been studied in the PRECiSE 1-4 trials. Adalimumab has been extensively studied in CLASSIC I and II, as well as the GAIN and CHARM trials. Several thousands of CD patients treated with infliximab have also been followed through the TREAT registry, in order to determine long-term effects of the therapy. Although each of these trials have provided considerable data regarding individual agents, these agents have not been directly evaluated in a head-to-head comparison. Varying clinical designs and endpoints make comparison of data across clinical trials a complex task. This monograph will focus on methods and criteria to consider when judging similarities and differences among these biologic agents.

Original languageEnglish (US)
Pages (from-to)1
Number of pages1
JournalGastroenterology and Hepatology
Volume4
Issue number3
StatePublished - Mar 2008

Fingerprint

Biological Therapy
Crohn Disease
Clinical Trials
Biological Factors
Therapeutics
Mesalamine
6-Mercaptopurine
Azathioprine
Inflammatory Bowel Diseases
Pharmaceutical Preparations
Registries
Adrenal Cortex Hormones
Anti-Inflammatory Agents
Tumor Necrosis Factor-alpha
Steroids
Cytokines
Anti-Bacterial Agents
Safety
Infliximab

ASJC Scopus subject areas

  • Gastroenterology
  • Hepatology

Cite this

Clinical trials in biologic therapy for Crohn's disease : Comparing designs and data. / Lichtenstein, Gary R.; Hanauer, Stephen B.; Loftus, Jr, Edward Vincent.

In: Gastroenterology and Hepatology, Vol. 4, No. 3, 03.2008, p. 1.

Research output: Contribution to journalArticle

@article{5ac165c2a48f4bf09ad792f1eac874ca,
title = "Clinical trials in biologic therapy for Crohn's disease: Comparing designs and data",
abstract = "Crohn's disease is a chronic inflammatory bowel disease with no known cure, estimated to occur in more than 500,000 Americans. Induction and long-term maintenance of remission are the major goals of Crohn's disease therapy. Over the past several decades, standard therapy for Crohn's disease patients has included immunomodulatory drugs such as azathioprine and 6-mercaptopurine, anti-inflammatory drugs such as 5-aminosalicylate, steroids, and antibiotics. Unfortunately, many patients become refractory to therapy over time or dependent on therapies such as corticosteroids, which are not feasible for long-term use. Over the past decade, several biologic agents have emerged with potential to induce response of active disease and maintain remission in Crohn's disease patients. Most of these agents, including infliximab, adalimumab, and certolizumab pegol, target the pro-inflammatory cytokine tumor necrosis factor. Several pivotal clinical trials have been conducted to investigate the safety and efficacy potential of these agents. Infliximab was evaluated in the key ACCENT I and II studies, while certolizumab pegol has been studied in the PRECiSE 1-4 trials. Adalimumab has been extensively studied in CLASSIC I and II, as well as the GAIN and CHARM trials. Several thousands of CD patients treated with infliximab have also been followed through the TREAT registry, in order to determine long-term effects of the therapy. Although each of these trials have provided considerable data regarding individual agents, these agents have not been directly evaluated in a head-to-head comparison. Varying clinical designs and endpoints make comparison of data across clinical trials a complex task. This monograph will focus on methods and criteria to consider when judging similarities and differences among these biologic agents.",
author = "Lichtenstein, {Gary R.} and Hanauer, {Stephen B.} and {Loftus, Jr}, {Edward Vincent}",
year = "2008",
month = "3",
language = "English (US)",
volume = "4",
pages = "1",
journal = "Gastroenterology and Hepatology",
issn = "1554-7914",
publisher = "Gastro-Hep Communications, Inc.",
number = "3",

}

TY - JOUR

T1 - Clinical trials in biologic therapy for Crohn's disease

T2 - Comparing designs and data

AU - Lichtenstein, Gary R.

AU - Hanauer, Stephen B.

AU - Loftus, Jr, Edward Vincent

PY - 2008/3

Y1 - 2008/3

N2 - Crohn's disease is a chronic inflammatory bowel disease with no known cure, estimated to occur in more than 500,000 Americans. Induction and long-term maintenance of remission are the major goals of Crohn's disease therapy. Over the past several decades, standard therapy for Crohn's disease patients has included immunomodulatory drugs such as azathioprine and 6-mercaptopurine, anti-inflammatory drugs such as 5-aminosalicylate, steroids, and antibiotics. Unfortunately, many patients become refractory to therapy over time or dependent on therapies such as corticosteroids, which are not feasible for long-term use. Over the past decade, several biologic agents have emerged with potential to induce response of active disease and maintain remission in Crohn's disease patients. Most of these agents, including infliximab, adalimumab, and certolizumab pegol, target the pro-inflammatory cytokine tumor necrosis factor. Several pivotal clinical trials have been conducted to investigate the safety and efficacy potential of these agents. Infliximab was evaluated in the key ACCENT I and II studies, while certolizumab pegol has been studied in the PRECiSE 1-4 trials. Adalimumab has been extensively studied in CLASSIC I and II, as well as the GAIN and CHARM trials. Several thousands of CD patients treated with infliximab have also been followed through the TREAT registry, in order to determine long-term effects of the therapy. Although each of these trials have provided considerable data regarding individual agents, these agents have not been directly evaluated in a head-to-head comparison. Varying clinical designs and endpoints make comparison of data across clinical trials a complex task. This monograph will focus on methods and criteria to consider when judging similarities and differences among these biologic agents.

AB - Crohn's disease is a chronic inflammatory bowel disease with no known cure, estimated to occur in more than 500,000 Americans. Induction and long-term maintenance of remission are the major goals of Crohn's disease therapy. Over the past several decades, standard therapy for Crohn's disease patients has included immunomodulatory drugs such as azathioprine and 6-mercaptopurine, anti-inflammatory drugs such as 5-aminosalicylate, steroids, and antibiotics. Unfortunately, many patients become refractory to therapy over time or dependent on therapies such as corticosteroids, which are not feasible for long-term use. Over the past decade, several biologic agents have emerged with potential to induce response of active disease and maintain remission in Crohn's disease patients. Most of these agents, including infliximab, adalimumab, and certolizumab pegol, target the pro-inflammatory cytokine tumor necrosis factor. Several pivotal clinical trials have been conducted to investigate the safety and efficacy potential of these agents. Infliximab was evaluated in the key ACCENT I and II studies, while certolizumab pegol has been studied in the PRECiSE 1-4 trials. Adalimumab has been extensively studied in CLASSIC I and II, as well as the GAIN and CHARM trials. Several thousands of CD patients treated with infliximab have also been followed through the TREAT registry, in order to determine long-term effects of the therapy. Although each of these trials have provided considerable data regarding individual agents, these agents have not been directly evaluated in a head-to-head comparison. Varying clinical designs and endpoints make comparison of data across clinical trials a complex task. This monograph will focus on methods and criteria to consider when judging similarities and differences among these biologic agents.

UR - http://www.scopus.com/inward/record.url?scp=42549145819&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=42549145819&partnerID=8YFLogxK

M3 - Article

VL - 4

SP - 1

JO - Gastroenterology and Hepatology

JF - Gastroenterology and Hepatology

SN - 1554-7914

IS - 3

ER -